F. Vollenhoven

Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.

B. Venmans, A. van der Wekken, A. ten Brinke, 2023, The Cochrane database of systematic reviews.